U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. FDA Updates and Press Announcements on NDMA in Metformin
  1. Drug Safety and Availability

FDA Updates and Press Announcements on NDMA in Metformin

 

Search metformin products recalls list

QA on NDMA in metformin

Nitrosamine Impurities in Medications


Update [11/4/2020]  FDA is alerting patients and health care professionals to Nostrum Laboratories’ voluntary recall of four lots of extended release (ER) metformin (two lots of 500 mg tablets and two lots of 750 mg tablets). The company is recalling metformin because it may contain N-nitrosodimethylamine (NDMA) above the acceptable intake limit.

FDA publishes a recalled metformin list including details about metformin products that have been recalled. Patients taking recalled ER metformin should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional. FDA recommends that health care professionals continue to prescribe metformin when clinically appropriate; FDA testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).

Update [10/5/2020] FDA is alerting patients and health care professionals to two voluntary recalls of extended release (ER) metformin by Marksans Pharma and Sun Pharmaceutical Industries. The companies are recalling metformin because it may contain N-nitrosodimethylamine (NDMA) above the acceptable intake limit.

  • Marksans expanded its voluntary recall to include 76 additional unexpired lots of metformin ER tablets (500 mg and 750mg) labeled as Time-Cap Labs.
  • Sun voluntarily recalled one lot of Riomet ER, metformin hydrochloride for extended release oral suspension (500 mg per 5 mL).

FDA publishes a recalled metformin list including details about metformin products that have been recalled.

Patients taking recalled ER metformin should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional. FDA recommends that health care professionals continue to prescribe metformin when clinically appropriate.

The agency’s testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).

FDA-published testing method to provide an option for regulators and industry to detect NDMA impurities
The links below are to FDA-published testing methods to provide an option for regulators and industry to detect nitrosamine impurities in metformin drug substances and drug products. These methods should be validated by the user if the resulting data are used to support a required quality assessment of the API or drug product, or if the results are used in a regulatory submission.
  • LC-HRMS method: an LC-MS method for the detection of NDMA in metformin drug substance and drug products.
  • LC-ESI-HRMS method: an LC-HRMS method for the measurement of amounts of eight nitrosamine impurities in metformin drug substance and drug products

 

 

Back to Top